Tourmaline Bio, INC Form 4 insider transactions
Insider transactions: buys and sells by directors, officers and ten percent owners, filed within two business days of the trade.
Tourmaline Bio director Clay B. Siegall disposed of all his employee stock options as part of the company's acquisition by Novartis AG for $48.00 per share.
Tourmaline Bio Director Parvinder Thiara disposed of all common stock and stock options as part of the company's acquisition by Novartis AG for $48.00 per share.
Tourmaline Bio director Sapna Srivastava disposed of all common stock and stock options following the completion of the acquisition by Novartis AG for $48.00 per share.
Mark McDade, a director of Tourmaline Bio, Inc., disposed of all his direct and indirect holdings and stock options following the company's acquisition by Novartis AG for $48.00 per share.
Tourmaline Bio Director Aaron Kantoff disposed of all common stock and cashed out stock options following the company's acquisition by Novartis AG for $48.00 per share.
Caley Castelein, a Director and 10% Owner of Tourmaline Bio, Inc., reported the disposition of common stock and options following the company's acquisition by Novartis AG for $48.00 per share.
Kevin Bruce Johnson, Chief Regulatory Officer of Tourmaline Bio, Inc., disposed of all his common stock and stock options as part of the company's acquisition by Novartis AG for $48.00 per share.
Tourmaline Bio's Chief Technology Officer, Susan Dana Jones, disposed of common stock and stock options following the company's acquisition by Novartis AG for $48.00 per share.
W. Bradford Middlekauff, CBO, GC, and Secretary of Tourmaline Bio, disposed of all his common stock and stock options as part of the company's acquisition by Novartis AG.
Tourmaline Bio's CFO, Ryan F. Robinson, disposed of all his common stock and employee stock options as part of the company's acquisition by Novartis AG for $48.00 per share.
Tourmaline Bio, Inc. CEO Sandeep Chidambar Kulkarni disposed of all beneficial ownership following the company's acquisition by Novartis AG for $48.00 per share.
Tourmaline Bio Director Aaron Kantoff reported gifting 5,000 shares of common stock for charitable purposes.
Tourmaline Bio's CFO, Ryan F. Robinson, acquired 14,366 shares of common stock by exercising employee stock options at $13.92 per share.
Tourmaline Bio CEO Sandeep Kulkarni exercised employee stock options, acquiring 25,316 shares of common stock at $7.90 per share.
Tourmaline Bio Director Caley Castelein reported a gift of 522 common shares, reducing his direct beneficial ownership.
Kevin Bruce Johnson, Chief Regulatory Officer of Tourmaline Bio, Inc., donated 6,250 shares of common stock to a donor-advised fund.
Tourmaline Bio, Inc. Director Aaron Kantoff exercised stock options to acquire 47,890 shares of common stock, increasing his direct beneficial ownership to 93,281 shares.
Tourmaline Bio, Inc. Director Aaron Kantoff has been granted 16,800 stock options with an exercise price of $18.73, aligning his interests with shareholder value.
Tourmaline Bio, Inc. Director Parvinder Thiara was granted 16,800 stock options with an exercise price of $18.73, vesting over approximately one year.
Tourmaline Bio, Inc. Director Sapna Srivastava has been granted 16,800 stock options with an exercise price of $18.73, aligning her incentives with future company performance.
Tourmaline Bio, Inc. Director and 10% Owner Clay B. Siegall was granted 16,800 stock options with an exercise price of $18.73, vesting on the earlier of June 4, 2026, or the 2026 Annual Meeting of Stockholders.
Tourmaline Bio, Inc. Director Caley Castelein was granted 16,800 stock options with an exercise price of $18.73, vesting on the earlier of June 4, 2026, or the 2026 Annual Meeting of Stockholders.
Tourmaline Bio, Inc. director Mark McDade was granted 16,800 stock options with an exercise price of $18.73, vesting on the earlier of June 4, 2026, or the 2026 Annual Meeting of Stockholders.
Tourmaline Bio's CEO, Sandeep Chidambar Kulkarni, reports the acquisition of 226,000 employee stock options.
Ryan F. Robinson, CFO of Tourmaline Bio, Inc., was granted employee stock options for 58,000 shares on January 27, 2025.
W. Bradford Middlekauff, CBO, GC and Secretary of Tourmaline Bio, Inc., reports the acquisition of employee stock options.
Susan Dana Jones, Chief Technology Officer of Tourmaline Bio, Inc., acquired 58,000 employee stock options on January 27, 2025.
Kevin Bruce Johnson, Chief Regulatory Officer of Tourmaline Bio, Inc., was granted stock options for 58,000 shares on January 27, 2025.
CEO Sandeep Chidambar Kulkarni of Tourmaline Bio, Inc. recently purchased 1,779 shares of common stock at an average price of $14.85.
Tourmaline Bio CEO Sandeep Chidambar Kulkarni reports the acquisition of 5,221 shares of common stock at an average price of $13.79.